Supplementary materials: Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis

These are peer-reviewed supplementary materials for the article 'Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis' published in the Journal of Comparative Effectiveness Research.Supplementary 1: Search StrategySupplementary 2: Study Characteristics Supplementary 3: Forest Plot for Subgroup Analysis of Studies Including ACS Patients Supplementary 4: Quality Assessment Aim: To summarize the evidence in terms of efficacy and safety of head-to-head studies of high-intensity statins regardless of the underlying population. Materials & methods: A systematic review and meta analysis was conducted to summarize the effect sizes in randomized controlled trials and cohort studies that compared high-intensity statins. Results: Based on 44 articles, similar effectiveness was observed across the statins in reducing LDL levels from baseline. All statins were observed to have similar adverse drug reactions (ADRs), although higher dosages were associated with more ADRs. Based on a pooled quantitative analysis of atorvastatin 80 mg versus rosuvastatin 40 mg, rosuvastatin was statistically more effective in reducing LDL. Conclusion: This review further confirms that high-intensity statins reduce LDL by ≥50%, favoring rosuvastatin over atorvastatin. Additional data are needed to confirm the clinical significance on cardiovascular outcomes using real-world studies.

本数据集为发表在《比较疗效研究杂志》上的文章《高强度他汀类药物的比较疗效与安全性：系统评价与荟萃分析》的同行评审补充材料。补充材料1：检索策略；补充材料2：研究特征；补充材料3：包括ACS患者亚组分析的森林图；补充材料4：质量评估。目标：旨在总结高强度他汀类药物在直接比较研究中的疗效与安全性证据，无论其基础人群。材料与方法：通过对随机对照试验和队列研究中高强度他汀类药物的比较进行系统评价与荟萃分析，总结效应量。结果：基于44篇文章的研究，观察到所有他汀类药物在降低基线LDL水平方面具有相似的有效性。所有他汀类药物均观察到具有相似的不良药物反应（ADRs），尽管较高剂量与更多ADRs相关。基于阿托伐他汀80 mg与瑞舒伐他汀40 mg的合并定量分析，瑞舒伐他汀在降低LDL方面显示出统计学上的更高有效性。结论：本综述进一步证实，高强度他汀类药物能够降低LDL水平≥50%，且瑞舒伐他汀相对于阿托伐他汀更具优势。需要进一步的数据以通过真实世界研究证实其在心血管结局方面的临床意义。